GL Biochem Receives the "Best Peptide Synthesis Solution Provider in Asia" Award from Life Sciences Review for 2026

GL Biochem Awarded Asia’s Top Peptide Synthesis Provider 2026

On January 30, 2026, GL Biochem (Shanghai) Ltd. was named the Top Peptide Synthesis Solution in Asia 2026 by Life Sciences Review (ISSN 2831-8331), an international magazine that covers leading companies and developments in the life sciences sector.

The award recognizes GL Biochem’s excellence in custom peptide synthesis, quality assurance, and customer service, as well as its commitment to supporting researchers and organizations worldwide.

Proven Peptide Expertise Since 1998

Founded in Shanghai in 1998, GL Biochem has developed a comprehensive suite of services that cover the entire peptide production lifecycle. Its team supports customers from early-stage research and small-scale test batches to larger production runs.

In its award feature, Life Sciences Review interviewed Dr. Hongyan Xu, CEO and President of GL Biochem. The article details how the company integrates research, process development, and manufacturing under one roof.

This end-to-end capability allows GL Biochem to grow with its clients. A research team might start by ordering a small amount of a peptide to validate a hypothesis, but later require larger volumes for extended studies. GL Biochem ensures continuity across all these development stages.

Custom Peptides and Complex Sequences

GL Biochem currently produces over 10,000 purified custom peptide sequences every month. Its portfolio includes complex sequences, long peptides comprising more than 50 amino acids, and peptides with specialized modifications.

Custom synthesis enables clients to order peptides tailored to their specific project requirements, including unique sequences, lengths, and modifications. Depending on the intended application, some projects require short and simple chains, while others need extended sequences or specific alterations to suit a particular study.

GL Biochem’s manufacturing capabilities span the full spectrum of these demands, including clinical-grade production.

A Legacy of Quality

GL Biochem proudly reports 28 years of operation without a single major quality incident. The company maintains ISO 9001 certification and adheres to quality systems aligned with Good Manufacturing Practice (GMP).

Quality control is essential because researchers depend on peptides that consistently meet agreed-upon standards. Reliable materials allow teams to accurately compare results and plan subsequent experiments. In drug development, strict quality assurance becomes increasingly critical as projects advance toward clinical application.

The award feature highlights quality as the cornerstone of GL Biochem’s service, alongside its technical expertise and robust production capacity.

Empowering Global Life Science Research

GL Biochem serves pharmaceutical companies, biotech startups, contract research organizations (CROs), and academic institutions in over 100 countries.

These partners utilize peptides across a wide array of applications, including drug discovery, gene editing, cell therapy, vaccine development, and diagnostic research. Each field presents distinct requirements for sequences, quantities, and quality benchmarks.

By offering both custom synthesis and scalable manufacturing, GL Biochem ensures a stable supply of peptides for projects at any stage of development.

A Vision for the Future of Peptide Manufacturing

In his exclusive interview with Life Sciences Review, Dr. Xu stated:

“Our mission is centered on promoting the industrialization of peptide technology and empowering global life science innovation through efficient, green, and large-scale production.”

In essence, the company is dedicated to making peptide technology more accessible and scalable, with core goals focused on manufacturing efficiency, sustainable practices, and advancing global scientific research.

Translating Peptide Science into Skincare

Leveraging its deep scientific heritage, GL Biochem has also entered the consumer skincare market through its brand, JIMEIJIAER.

In January 2026, JIMEIJIAER successfully registered its manufacturing facility and listed its products with the U.S. Food and Drug Administration (FDA) as part of its market entry strategy. This registration should not be interpreted as FDA endorsement of the product’s efficacy or safety.

For consumers interested in experiencing the company’s research-backed skincare solutions, explore the JIMEIJIAER peptide skincare line. The brand serves as a tangible extension of GL Biochem’s scientific expertise beyond the laboratory.

Read the Full Award Feature

The Life Sciences Review article offers a comprehensive look into GL Biochem’s history, technical capabilities, and unwavering commitment to quality. It also features Dr. Xu’s insights on the company’s mission and strategic direction.

You can read the full feature on the Life Sciences Review website.